semagacestat
Small moleculeexperimental
Semagacestat (LY-450139) was a candidate drug for a causal therapy against Alzheimer's disease. It was originally developed by Eli Lilly and Elan, and clinical trials were conducted by Eli Lilly. Phase III trials included over 3000 patients, but in August 2010, a disappointing interim analysis, in which semagacestat performed worse than the placebo, led to the trials being stopped. — Wikipedia
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
3
Phase 4
0
Earliest trial started Oct 1, 2005 (NCT00244322)
Timeline
Indications
Studied for
Mechanism of action
- Gamma-secretaseINHIBITOR
Gamma-secretase inhibitor
Decreases dose-dependently Aß production in the human central nervous system
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1C(=O)N(C)CCc2ccccc21- Mol. weight
- 361.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSemagacestat ↗
- ChEMBLCHEMBL520733 ↗
Also known as
- ly411575
- ly 411575
- ly 411,575
- ly-411575
- ly-411,575
- ly411,575
- ly450139
- ly450139
- ly450139
- ly 450139
- ly-450139
- ly-450139
- n2-(2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-n1-(5-methyl-6-oxo-6,7-dihydro-5h-dibenzo(b,d)azepin-7-yl)alaninamide
- n2-((2s)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-n1-((7s)-5-methyl-6-oxo-6,7-dihydro-5h-dibenzo(b,d)azepin-7-yl)-l-alaninamide
- semagacestat
- semagacestat
- semagacestat
- semagacestat
- semagacestat
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01035138 | Phase 3 | Dec 1, 2009 | Eli Lilly |
| NCT00762411 | Phase 3 | Sep 1, 2008 | Eli Lilly |
| NCT00594568 | Phase 3 | Mar 1, 2008 | Eli Lilly |
| NCT00765115 | Phase 1 | Jul 1, 2006 | Eli Lilly |
| NCT00244322 | Phase 2 | Oct 1, 2005 | Eli Lilly |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 5 | 5 | 3 | 2005 |
1 organizations
Page 1 / 1